Clinical value of serum cytokeratin 19 fragements (CYFRA21-1) and serum tumor marker carcinoembryonic antigen (CEA) in the diagnosis of non-small cell lung cancer (NSCLC)

Abstract

Objective To evaluate the clinical value of cytokeratin 19 fragements (CYFRA21-1) and serum tumor marker (TM) carcinoembryonic antigen (CEA) in the diagnosis of non-small cell lung cancer (NSCLC). Methods 63 patients with NSCLC (including squamous cell carcinoma and adenocarcinoma) were selected from May 2014 to December 2016 as observation group, 37 patients with benign lung lesions as control group A, and 33 healthy subjects as control group B. The observation group was subdivided according to the TNM stage. Serum CYFRA21-1 and CEA levels in each group were observed. Results Serum levels of CYFRA21-1 and CEA were correlated with histological type, the level of CEA in lung adenocarcinoma group was significantly higher than that in lung squamous cell carcinoma group (P stage Ⅲ > stage Ⅱ > stage Ⅰ (P<0.05). The sensitivity and accuracy of CYFRA21-1, CEA combined detection were significantly higher than those of single detection. Conclusions Serum levels of CYFRA21-1 and CEA are associated with histological type and clinical stage of NSCLC. The level of CEA is higher in lung adenocarcinoma, while the level of CYFRA21-1 is higher in lung squamous cell carcinoma. The more advanced the clinical stage is, the higher the level of TM is. The sensitivity of single TM detection is low, and the combined detection of serum CYFRA21-1 and CEA can improve the sensitivity and accuracy. Key words: Non-small cell lung cancer; Tumor marker; Cytokeratin 19 fragements; Carcinoembryonic antigen